ALNYLAM PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 2.25 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2026-06-30 was 2.25M shares.
- ALNYLAM PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-09-30 was 1.58M shares.
- ALNYLAM PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-06-30 was 0.00 shares.
- ALNYLAM PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-09-30 was 0.00 shares, a 100.00% decline year-over-year.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month |
|---|---|---|---|
| 2026-06-30 | 2.25M shares 10-Q · filed 2026-07-30 | 2.25M shares 10-Q · filed 2026-07-30 | |
| 2025-09-30 | 1.58M shares 10-Q · filed 2025-10-30 | 0.00 shares 10-Q · filed 2025-10-30 | |
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-07-30 | 0.00 shares 10-Q · filed 2026-07-30 | |
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-10-30 | 0.00 shares 10-Q · filed 2025-10-30 | |
| 2023-09-30 | 3.62M shares 10-Q · filed 2024-10-31 | 0.00 shares 10-Q · filed 2024-10-31 | |
| 2022-09-30 | 0.00 shares 10-Q · filed 2023-11-02 | 0.00 shares 10-Q · filed 2023-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |